# Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

> **NCT00410592** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 90 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Esomeprazole 40mg
- **DRUG:** Pantoprazole 40mg
- **DRUG:** Lansoprazole 30mg

## Key facts

- **NCT ID:** NCT00410592
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2009-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410592, "Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00410592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*